AR070232A1 - Derivados de (beta)-aminoacidos - Google Patents

Derivados de (beta)-aminoacidos

Info

Publication number
AR070232A1
AR070232A1 ARP090100201A ARP090100201A AR070232A1 AR 070232 A1 AR070232 A1 AR 070232A1 AR P090100201 A ARP090100201 A AR P090100201A AR P090100201 A ARP090100201 A AR P090100201A AR 070232 A1 AR070232 A1 AR 070232A1
Authority
AR
Argentina
Prior art keywords
cr9r10
propionamide
dihydro
oxo
phenyl
Prior art date
Application number
ARP090100201A
Other languages
English (en)
Inventor
Christine Charon
Stefan Bender
Lars Thore Burgdorf
Johannes Gleitz
Norbert Beier
Ulrich Emde
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of AR070232A1 publication Critical patent/AR070232A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)

Abstract

Compuestos heterocíclicos de la formula 1 en donde R1 denota A, Ar o Het, R2, R2', R2ö cada uno, independientemente entre sí, denotan H, A, OA o Hal, R3 denota Het; R4, R5 denotan H, R6 denota H, A, Ar o Het; R7, R8 denotan H o R7 y R8 juntos denotan =O, R9, R10, R11 cada uno, independientemente entre sí, denotan H, A, Ar o Het, A denota alquilo no ramificado o ramificado C1-10, en el cual uno o dos grupos CH2 no adyacentes se pueden reemplazar con O, S, SO, SO2, NH, NA', NAr, NHet y/o con grupos -CH=CH- y/o además 1-7 átomos de H se pueden reemplazar con OH, F, Cl, Br, =S, =NR9 y/o =O o denota cicloalquilo C3-7, el cual no se sustituye, o se sustituye con uno, dos o tres =O, F, Cl, OH, OA', OAr', OHet', SOnA', SOnAr', SOnHet', NH2, NHA', NA'2, NHAr' y/o NHHet', A' denota alquilo no ramificado o ramificado C1-6 en el cual 1-7 átomos de H se pueden reemplazar con F y/o Cl, Alk denota alquileno no ramificado o ramificado con 1, 2, 3 o 4 átomos de C, Ar denota fenilo, naftilo o bifenilo, cada uno de los cuales no se sustituye o se sustituye con uno, dos, tres, cuatro o cinco A, Hal, (CR9R10)mAr', (CR9R10)mHet', O(CR9R10)mR11, S(O)nR9, NH2, NHA', NA'2, NHAr', NHHet', NO2, CN, COOR9, CON(R9R10)2, NR9COR10, NR9CON(R10R11)2, NR9SOnR10, COR9, SO3H, SOnN(R9R10)2, O-Alk-N(R9R10)2, O-(CR9R10)mCON(R9R10)2, O-Alk-NR9COR10, O(CR9R10)mHet', O(CR9R10)mAr', S(O)n(CR9R10)mHet' y/o S(O)n(CR9R10)mAr', Het denota un heterociclo saturado, insaturado o aromático mono o bicíclico con 1 a 4 átomos de N, O y/o S, los cuales se pueden sustituir con uno, dos o tres Hal, A, (CR9R10)mAr', (CR9R10)mHet', O(CR9R10)mAr', O(CR9R10)mHet', (CR9R10)mcicloalquilo, (CR9R10)mOR12, (CR9R10)mN(R11)2, NO2, CN, (CR9R10)mCOOR11, O(CR9R10)mCOOR11, (CR9R10)mCON(R11)2, (CR9R10)mCONR11N(R9R10)2, O(CR9R10)CON(R11)2, O(CR9R10)mCONR11N(R9R10)2, (CR9R10)mNR11COA, NR9CON(R10R11)2, (CR9R10)mNR11SO2A, COR9, SO2N(R9R10)2, S(O)nA, =S, =NR2 y/o =O (oxígeno carbonilo), Ar' denota fenilo, naftilo o bifenilo, cada uno de los cuales no se sustituye o se sus4ituye con uno, dos o tres Hal, A, OR9, N(R9R10)2, NO2, CN, COOR9, CON(R9R10)2, NR9COA, NR9CON(R10R11)2, NR9SO2A, COR9, SO2N(R9R10)2, S(O)nA, (CR9R10)mCOOR11 y/o O(CR9R10)mCOOR11; Het' denota un heterociclo saturado, insaturado o aromático mono o bicíclico con 1 a 4 átomos de N, O y/o S, los cuales se pueden sustituir con uno, dos o tres Hal, A, OR9, N(R9R10)2, NO2, CN, COOR9, CON(R9R10)2, NR9COA, NR9SO2A, COR9, SO2N(R9R10)2, S(O)nA, =S, =NR9 y/o =O (oxígeno carbonilo), Hal denota F, Cl, Br o I, m denota 0, 1, 2, 3 o 4, n denota 0, 1 o 2, y sales aceptables para uso farmacéutico y estereoisomeros de los mismos, incluyendo mezclas de los mismos en todas las proporciones, excluyendo los compuestos seleccionados entre el grupo N-(5-Bromo-piridin-2-il) -3-(1-oxo-1,3-dihidro-isoindol-2-il)-3-(3,4,5- trimetoxi-fenil)-propionamida, N-(5-Cloro-piridin-2-il)-3-(1-oxo-1,3-dihidro-isoindol-2-il)-3-(3,4,5-trimetoxi-fenil)-propionamida, 3-(3,4-Dimetoxi-fenil)-3-(1-oxo-1,3-dihidro-isoindol-2-il)-N-piridin-2- il-propionamida, 3-(1-Oxo-1,3-dihidro-isoindol-2-il)-N-piridin-2-il-3-(3,4,S-trimetoxi-fenil)-propionamida, N-(5-Bromo-piridin-2-il)-3-(3,4-dimetoxi-fenil)-3-(1-oxo-1,3-dihidro-isoindol-2-il)-propionamida, N-(5-Cloro-piridin-2-il)-3-(3,4-dimetoxi-fenil)-3-(1-oxo-1,3-dihidro- isoindol-2-il)-propionamida, N- (5-Metil-piridin-2-il)-3-(1-oxo-1,3-dihidro-isoindol-2-il)-3-(3,4,5-trimetoxi-fenil)-propionamida, N-(5-Cloro-piridin-2-il)-3-(4-fluoro-fenil)-3-(1-oxo-1,3-dihidro-isoindol-2-il)-propionamida, 3-(3,4-Dimetoxi-fenil)-N-(5-metil-piridin-2-il)-3-(1-oxo-2,3-dihidro-isoindol-2-il)-propionamida, N-(5-Bromo-piridin-2-il)-3-(1-oxo-1,3-dihidro-isoindol-2-il)-3-p-tolil-propionamida, 3-(1-Oxo-2,3-dihidro-isoindol-2-il)-N-piridin-2-il-3-tiofen-2-il-propionamida, 3-(4-Metoxi-fenil)-N-(6-metil-piridin-2-il)-3-(1-oxo-1,3-dihidro- isoindol-2-il)-propionamida, N-(6-Metil-piridin-2-il)-3-(1-oxo-1,3-dihidro-isoindol-2-i1)-3-(3,4,5- trimetoxi-fenil)-propionamida, 3-(4-Metoxi-fenil)-N-(4-metil-piridin-2-il)-3-(1-oxo-1,3-dihidro-isoindol-2-il)-propionamida, 3-(3,4-Dimetoxi-fenil)-N-(6-metil-piridin-2-il)-3-(1-oxo-1,3-dihidro- isoindol-2-il)-propionamida, 3-(4-Metoxi-fenil)-N-(5-metil-piridin-2-il)-3-(1-oxo-1,3-dihidro-isoindol-2-il)-propionamida, 3-(4-Metoxi-fenil)-3-(1-oxo-1,3-dihidro-isoindol-2-il)-N-piridin-2-il-propionamida, N-(4-Metil-tiazol-2-il)-3-(1-oxo-1,3-dihidro-isoindol-2-il)-3-)3,4,5-trimetoxi-fenil)-propionamida, 3-(1-Oxo-1,3-dihidro-isoindol-2-il)-N-tiazol-2-il-3-(3,4,5-trimetoxi-fenil)-propionamida. Como activadores de glucoquinasa y que se pueden usar en la prevencion y/o tratamiento de diabetes tipo 1 y 2, obesidad, neuropatías y/o nefropatías, composicion farmacéutica y usos y proceso de preparacion.
ARP090100201A 2008-01-24 2009-01-23 Derivados de (beta)-aminoacidos AR070232A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08001305 2008-01-24

Publications (1)

Publication Number Publication Date
AR070232A1 true AR070232A1 (es) 2010-03-25

Family

ID=40386192

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090100201A AR070232A1 (es) 2008-01-24 2009-01-23 Derivados de (beta)-aminoacidos

Country Status (21)

Country Link
US (1) US8431602B2 (es)
EP (1) EP2231640B1 (es)
JP (1) JP5623914B2 (es)
KR (1) KR20100110367A (es)
CN (1) CN101925596B (es)
AR (1) AR070232A1 (es)
AU (1) AU2008348817B2 (es)
BR (1) BRPI0821827A2 (es)
CA (1) CA2712998A1 (es)
CY (1) CY1112919T1 (es)
DK (1) DK2231640T3 (es)
EA (1) EA017775B1 (es)
ES (1) ES2388475T3 (es)
HR (1) HRP20120510T1 (es)
IL (1) IL206904A0 (es)
MX (1) MX2010007926A (es)
PL (1) PL2231640T3 (es)
PT (1) PT2231640E (es)
SI (1) SI2231640T1 (es)
WO (1) WO2009092432A1 (es)
ZA (1) ZA201006002B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
DK3365334T3 (da) 2015-10-21 2024-09-23 Otsuka Pharma Co Ltd Benzolactamforbindelser som proteinkinaseinhibitorer
GB201706327D0 (en) 2017-04-20 2017-06-07 Otsuka Pharma Co Ltd A pharmaceutical compound

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698579A (en) * 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides
US6482951B2 (en) * 2000-12-13 2002-11-19 Hoffmann-La Roche Inc. Isoindolin-1-one glucokinase activators
CN1713905A (zh) * 2002-10-15 2005-12-28 细胞基因公司 用于治疗骨髓增生异常综合征的选择性细胞因子抑制药
CA2511843C (en) * 2002-12-30 2012-04-24 Celgene Corporation Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses
CN101309585A (zh) * 2004-10-28 2008-11-19 细胞基因公司 使用pde4调节剂治疗和控制中枢神经系统损伤的方法和组合物
WO2007143434A2 (en) 2006-05-31 2007-12-13 Takeda San Diego, Inc. Indazole and isoindole derivatives as glucokinase activating agents

Also Published As

Publication number Publication date
CN101925596A (zh) 2010-12-22
EP2231640B1 (en) 2012-06-06
DK2231640T3 (da) 2012-07-16
EA201001174A1 (ru) 2011-02-28
CN101925596B (zh) 2014-05-28
MX2010007926A (es) 2010-08-09
US20100331346A1 (en) 2010-12-30
CY1112919T1 (el) 2016-04-13
WO2009092432A1 (en) 2009-07-30
AU2008348817B2 (en) 2011-12-15
PL2231640T3 (pl) 2012-09-28
IL206904A0 (en) 2010-12-30
PT2231640E (pt) 2012-08-23
ES2388475T3 (es) 2012-10-15
AU2008348817A1 (en) 2009-07-30
US8431602B2 (en) 2013-04-30
BRPI0821827A2 (pt) 2015-06-16
KR20100110367A (ko) 2010-10-12
ZA201006002B (en) 2011-04-28
CA2712998A1 (en) 2009-07-30
EP2231640A1 (en) 2010-09-29
JP2011510029A (ja) 2011-03-31
HRP20120510T1 (hr) 2012-07-31
SI2231640T1 (sl) 2012-09-28
EA017775B1 (ru) 2013-03-29
JP5623914B2 (ja) 2014-11-12

Similar Documents

Publication Publication Date Title
AR070232A1 (es) Derivados de (beta)-aminoacidos
AR095312A1 (es) Compuestos de biarilamida como inhibidores de cinasa
AR054035A1 (es) Derivados benzodioxano y benzodioxolano y uso de los mismos
AR086817A1 (es) Compuestos inhibidores de la fosfodiesterasa tipo 10a
AR056979A1 (es) Derivados de dihidrobenzofuranos y usos de los mismos
AR082109A1 (es) Derivados de bipiridilo
AR067506A1 (es) Derivados de quinazolinamida
AR068749A1 (es) Derivados de n-(pirazol-3-il)-benzamida
AR068748A1 (es) Derivados de piridina activadores de glucoquinasa
AR084507A1 (es) Derivados de indazoliltriazol
JP2017507983A (ja) 新規な３−インドール置換誘導体、医薬組成物、および使用方法
AR079690A1 (es) Derivados heterociclicos de pirrol[2,3-b]piridina, composiciones farmaceuticas que los contienen, procedimiento para prepararlos y uso de los mismos como agentes anticancer.
AR061735A1 (es) Derivados de indazol, composiciones farmaceuticas y uso de los mismos
EP3105225A1 (en) Novel 3-(indol-3-yl)-pyridine derivatives, pharmaceutical compositions and methods for use
AR086019A1 (es) COMPUESTOS DE PIRROLO SULFONAMIDA PARA MODULACION DE LA ACTIVIDAD DEL RECEPTOR HUERFANO g RELACIONADO AL RECEPTOR NUCLEAR HUERFANO RAR (RORg, NR1F3) Y PARA EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS Y AUTOINMUNES CRONICAS
AR091176A1 (es) Pirrodilina-2-carboxamidas sustituidas
AR071112A1 (es) Derivados de benzopirano y benzoxepina inhibidores de quinasaspi3k, utiles como agentes anticancer,y composiciones farmaceuticas que los contienen.
AR051675A1 (es) Derivados de 3-fenil-pirazol como moduladores del receptor 5-ht2a de la serotonina utiles para el tratamiento de trastornos relacionados con este
AR045761A1 (es) Derivados de 2-piridona como inhibidores de elastasa de neutrofilos
AR037907A1 (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
AR068658A1 (es) Derivados de tiazol
AR089944A1 (es) Derivados de tetrahidro-quinazolinona
AR068730A1 (es) Compuestos de diaril 1,2,4-oxadiazol,composiciones farmaceuticas que los contienen,proceso de preparacion y uso de los mismos como agentes inmunosupresores en el tratamiento de enfermedades autoinmunes y/o inflamatorias cronicas.
PE20141351A1 (es) Triazolopiridinas
AR082696A1 (es) Derivados heterociclicos nitrogenados de 1,2,4-oxadiazol, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades cardiovasculares e inflamatorias, entre otras

Legal Events

Date Code Title Description
FB Suspension of granting procedure
FB Suspension of granting procedure